MedPath

FDA Accepts Milestone's Cardamyst NDA for PSVT Treatment

  • The FDA has accepted Milestone Pharmaceuticals' NDA for Cardamyst (etripamil) nasal spray, a potential treatment for paroxysmal supraventricular tachycardia (PSVT).
  • Cardamyst is designed for patient self-administration, offering a rapid-response therapy to manage PSVT episodes without immediate medical oversight.
  • The PDUFA target date for the FDA's decision on Cardamyst is set for 10 months from the NDA acceptance date of May 26, 2024.
  • PSVT affects an estimated two million people in the U.S., and Cardamyst aims to provide a convenient and effective treatment option.
Milestone Pharmaceuticals announced that the FDA has accepted its New Drug Application (NDA) for Cardamyst (etripamil) nasal spray on May 26, 2024, marking a significant step toward a new treatment option for paroxysmal supraventricular tachycardia (PSVT). The FDA has set a Prescription Drug User Fee Act (PDUFA) target date 10 months from the acceptance date.

Addressing PSVT with Cardamyst

Cardamyst is designed as a self-administered therapy, potentially allowing patients to manage PSVT episodes without needing immediate medical intervention. PSVT, characterized by sudden, rapid heartbeats, affects an estimated two million people in the United States. These episodes can cause severe palpitations, shortness of breath, and chest discomfort, significantly impacting daily activities and quality of life.
"The FDA’s acceptance of our NDA for Cardamyst brings Milestone one step closer in our mission in providing a new, convenient and effective treatment option for patients with PSVT," said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals.

Clinical Data and Development

The Cardamyst clinical trial program represents the largest data package ever studied for an acute drug treatment intended for patient self-management of PSVT events. Milestone is actively preparing for the anticipated launch of etripamil under the brand name Cardamyst, which has been conditionally approved by the FDA.

The Need for New PSVT Treatments

Many healthcare providers express dissatisfaction with current PSVT treatment options, which often involve prolonged and costly emergency department visits or invasive cardiac ablation procedures. Cardamyst aims to fill this gap by providing a rapid-response therapy that patients can self-administer, potentially reducing the burden on healthcare systems and improving patient outcomes.

About Etripamil

Etripamil is a novel calcium channel blocker nasal spray being developed for the treatment of PSVT and AFib-RVR. It is designed to be a self-administered therapy, bypassing the need for immediate medical oversight. The clinical trial program for Cardamyst includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Accepts Crinetics' Paltusotine NDA for Acromegaly Treatment

The FDA has accepted Crinetics Pharmaceuticals' NDA for paltusotine for acromegaly, setting a target action date of September 25, 2025.

FDA Approves New Intravenous Formulation of Ustekinumab Biosimilar SELARSDI™

The FDA has approved a new intravenous formulation of SELARSDI™ (ustekinumab-aekn), a biosimilar to STELARA® (ustekinumab), expanding its potential use.

KalVista Seeks Global Approval for Oral HAE Treatment Sebetralstat

KalVista Pharmaceuticals has submitted Marketing Authorization Applications (MAAs) for sebetralstat in the UK, Switzerland, Australia, and Singapore.

FDA Grants Priority Review for Setmelanotide sNDA in Young Children with Rare Genetic Obesity

The FDA has accepted Rhythm Pharmaceuticals' sNDA for setmelanotide, seeking approval for children aged 2-6 with obesity due to Bardet-Biedl syndrome or POMC/LEPR deficiency.

FDA Grants Priority Review to Vimseltinib for Tenosynovial Giant Cell Tumor

The FDA has granted priority review to vimseltinib for treating tenosynovial giant cell tumor (TGCT), setting a PDUFA goal date of February 17, 2025.

FDA Accepts Stealth BioTherapeutics' NDA for Elamipretide in Barth Syndrome

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide, a potential first-in-class therapy for Barth syndrome, a rare genetic condition.

FDA Accepts Elamipretide NDA for Barth Syndrome Treatment

The FDA has accepted Stealth BioTherapeutics' NDA for elamipretide in treating Barth syndrome, a rare genetic condition with no approved therapies.

Verastem Oncology's Avutometinib and Defactinib Combination Receives FDA Priority Review for Recurrent KRAS Mutant LGSOC

The FDA has accepted Verastem Oncology's NDA for avutometinib plus defactinib with Priority Review for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Milestone Pharmaceuticals Resubmits NDA for Etripamil Nasal Spray for PSVT Treatment

Milestone Pharmaceuticals has resubmitted its New Drug Application (NDA) to the FDA for etripamil nasal spray, a potential treatment for paroxysmal supraventricular tachycardia (PSVT).

FDA Accepts Cytokinetics' NDA for Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction

The FDA has accepted Cytokinetics' New Drug Application (NDA) for omecamtiv mecarbil, a cardiac myosin activator, for treating heart failure with reduced ejection fraction (HFrEF).

Reference News

[1]
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for Cardamyst
drugs.com · May 29, 2024

Milestone Pharmaceuticals announced the FDA accepted their New Drug Application for Cardamyst (etripamil) nasal spray, i...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy